<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimoula, A.</style></author><author><style face="normal" font="default" size="100%">Fotellis, D.</style></author><author><style face="normal" font="default" size="100%">Aivalioti, E.</style></author><author><style face="normal" font="default" size="100%">Delialis, D.</style></author><author><style face="normal" font="default" size="100%">Polissidis, A.</style></author><author><style face="normal" font="default" size="100%">Patras, R.</style></author><author><style face="normal" font="default" size="100%">Kokras, N</style></author><author><style face="normal" font="default" size="100%">Stamatelopoulos, K.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Off-Target Effects of Antidepressants on Vascular Function and Structure</style></title><secondary-title><style face="normal" font="default" size="100%">Biomedicines</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">antidepressants</style></keyword><keyword><style  face="normal" font="default" size="100%">Atherosclerosis</style></keyword><keyword><style  face="normal" font="default" size="100%">cardiovascular</style></keyword><keyword><style  face="normal" font="default" size="100%">FMD (flow mediated dilation)</style></keyword><keyword><style  face="normal" font="default" size="100%">Hypertension</style></keyword><keyword><style  face="normal" font="default" size="100%">PWV (pulse wave velocity)</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Dec 28</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">1</style></number><edition><style face="normal" font="default" size="100%">20211228</style></edition><volume><style face="normal" font="default" size="100%">10</style></volume><isbn><style face="normal" font="default" size="100%">2227-9059 (Print)2227-9059</style></isbn><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Depression emerges as a risk factor for cardiovascular disease, and it is thought that successful antidepressant treatment may reduce such a risk. Therefore, antidepressant treatment embodies a potential preventive measure to reduce cardiovascular events in patients with depression. Accumulating evidence indicates that antidepressants have off-target effects on vascular dysfunction and in the early stages of atherosclerosis, which form the basis for cardiovascular disease (CVD) pathogenesis. In this context, we performed a thorough review of the evidence pertaining to the effects of different classes of antidepressant medications on hemodynamic and early atherosclerosis markers. The preclinical and clinical evidence reviewed revealed a preponderance of studies assessing selective serotonin reuptake inhibitors (SSRI), whereas other classes of antidepressants are less well-studied. Sufficient evidence supports a beneficial effect of SSRIs on vascular inflammation, endothelial function, arterial stiffening, and possibly delaying carotid atherosclerosis. In clinical studies, dissecting the hypothesized direct beneficial antidepressant effect of SSRIs on endothelial health from the global improvement upon remission of depression has proven to be difficult. However, preclinical studies armed with appropriate control groups provide evidence of molecular mechanisms linked to endothelial function that are indeed modulated by antidepressants. This suggests at least a partial direct action on vascular integrity. Further research on endothelial markers should focus on the effect of antidepressants on treatment responders versus non-responders in order to better ascertain the possible beneficial vascular effects of antidepressants, irrespective of the underlying course of depression.</style></abstract><accession-num><style face="normal" font="default" size="100%">35052735</style></accession-num><notes><style face="normal" font="default" size="100%">10.3390/biomedicines10010056</style></notes><custom1><style face="normal" font="default" size="100%">A.D., D.F., E.A., D.D., A.P., R.P. and K.S. declare no conflict of interest. N.K. has received honoraria and financial support from Janssen-Cilag, Lundbeck, Sanofi–Aventis, Medochemie Generics and Elpen S.A.</style></custom1><custom2><style face="normal" font="default" size="100%">PMC8773150</style></custom2><auth-address><style face="normal" font="default" size="100%">Department of Clinical Therapeutics, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, 80 Vas. Sofias Str., 11528 Athens, Greece.Department of Pharmacology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.Center of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 4 Soranou Efesiou St., 11527 Athens, Greece.First Department of Psychiatry, Eginition Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE2 4HH, UK.</style></auth-address><remote-database-provider><style face="normal" font="default" size="100%">NLM</style></remote-database-provider></record></records></xml>